SUN PHARMACEUTICAL INDUSTRIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,507 INR | +2.32% |
|
+3.27% | +19.64% |
| Sales 2024 | 485B 5.81B | Sales 2025 * | 535B 6.41B | Capitalization | 3,534B 42.36B |
|---|---|---|---|---|---|
| Net income 2024 | 95.76B 1.15B | Net income 2025 * | 111B 1.33B | EV / Sales 2024 | 8.02 x |
| Net cash position 2024 * | 97.98B 1.17B | Net cash position 2025 * | 178B 2.14B | EV / Sales 2025 * | 6.28 x |
| P/E ratio 2024 |
40.6
x | P/E ratio 2025 * |
32
x | Employees | 41,000 |
| Yield 2024 * |
0.84% | Yield 2025 * |
0.95% | Free-Float | 45.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sun Pharmaceutical Industries Ltd.
More recommendations
More press releases
More news
| 1 day | +1.62% | ||
| 1 week | +2.52% | ||
| Current month | +2.52% | ||
| 1 month | -1.24% | ||
| 3 months | -6.80% | ||
| 6 months | +20.76% | ||
| Current year | +18.83% |
1 week
1 377.20
1 499.40
1 month
1 377.201 564.00
Current year
1 257.151 638.85
1 year
977.301 638.85
3 years
652.701 638.85
5 years
312.001 638.85
10 years
312.001 638.85
| Managers | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Founder | 68 | 81-12-31 | |
| Director of Finance/CFO | - | 17-06-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 68 | 81-12-31 | |
Rama Bijapurkar
BRD | Director/Board Member | 67 | 21-05-20 |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 23-06-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.72% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 1,507 | +2.32% | 3 404 664 |
| 24-06-06 | 1,473 | -0.98% | 3,004,955 |
| 24-06-05 | 1,487 | +4.02% | 2,487,724 |
| 24-06-04 | 1,430 | -1.60% | 5,055,952 |
| 24-06-03 | 1,453 | -0.46% | 1,855,318 |
Delayed Quote NSE India S.E., June 07, 2024 at 03:13 am EDT
More quotes
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows:
- generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment;
- other (6%) : primarily active pharmaceutical ingredients.
At the end of March 2021, the group had 44 production plants worldwide.
Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
Sector
Pharmaceuticals
Calendar
2024-08-01
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,473
INR
Average target price
1,605
INR
Spread / Average Target
+8.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.83% | 42.33B | |
| +21.25% | 22.47B | |
| +17.07% | 15.25B | |
| +20.25% | 14.29B | |
| +53.74% | 12.6B | |
| -0.05% | 6.79B | |
| -11.11% | 6.71B | |
| -8.87% | 5.73B | |
| +14.27% | 5.47B | |
| +6.91% | 4.78B |
- Stock Market
- Equities
- SUNPHARMA Stock
